Low dose naltrexone for mental health is an off-label treatment that researchers are studying for certain psychiatric conditions, but current evidence is still limited. While some early studies suggest it may have potential benefits for a small group of people, it is not approved by the U.S. Food and Drug Administration (FDA) to treat mental health disorders and should only be used under the guidance of a qualified healthcare professional.
Low dose naltrexone (LDN) has received growing attention as clinicians and researchers continue exploring new approaches to managing complex mental health conditions. Unlike standard-dose naltrexone, which is FDA-approved to help treat alcohol use disorder and opioid use disorder, LDN is prescribed at much smaller doses—typically between 1 mg and 4.5 mg—and is considered an off-label medication. Off-label prescribing means a licensed healthcare provider prescribes an FDA-approved medication for a use that has not received FDA approval, based on their clinical judgment and the available evidence.
Interest in low dose naltrexone for mental health comes from research suggesting it may influence biological pathways involved in mood regulation, inflammation, and the body’s natural opioid system. These proposed effects have prompted investigations into its possible role as an additional treatment for conditions such as depression, anxiety, post-traumatic stress disorder (PTSD), and other psychiatric disorders. However, existing studies remain relatively small, and more high-quality clinical trials are needed before LDN can be considered a standard treatment for these conditions.
Because evidence continues to evolve, LDN is generally viewed as a potential adjunct rather than a replacement for established mental health treatments such as psychotherapy and evidence-based psychiatric medications. Decisions about its use should always be individualized and made in partnership with a qualified prescriber who can evaluate potential benefits, risks, medication interactions, and a person’s overall medical history. If you’re unsure who can prescribe mental health medication, our guide explains which healthcare professionals can evaluate symptoms, recommend treatment options, and safely manage psychiatric medications.
This guide explains what low dose naltrexone is, how it may work, what current research says about its use in mental health care, its potential risks and side effects, and when it may be appropriate to discuss this treatment with a healthcare professional.
What Is Low Dose Naltrexone?
Low dose naltrexone (LDN) is a form of naltrexone prescribed at much smaller doses than its FDA-approved formulation. While standard naltrexone is approved to treat alcohol use disorder and opioid use disorder, LDN is used off-label for conditions that are still being studied, including certain chronic pain disorders, autoimmune diseases, and some mental health conditions.
Naltrexone itself is an opioid receptor antagonist, meaning it temporarily blocks opioid receptors in the brain. At the standard 50 mg dose, this action helps reduce the rewarding effects of alcohol and prevents opioid medications from producing their usual effects. In contrast, LDN is typically prescribed in doses ranging from 1 mg to 4.5 mg, although the exact dose varies depending on the individual’s medical history and the clinician’s treatment plan.
Because these lower doses are not commercially available in the United States, LDN is often prepared by a licensed compounding pharmacy. Compounded medications can be appropriate when a patient needs a dose or formulation that is not manufactured by pharmaceutical companies. Patients should use reputable pharmacies that follow quality standards, since compounded medications are not reviewed by the FDA in the same way as commercially manufactured drugs.
Although LDN has attracted interest for psychiatric care, it has not been approved by the FDA to treat depression, anxiety, PTSD, bipolar disorder, or other mental health disorders. Healthcare professionals who prescribe it for these conditions rely on clinical judgment, individual patient needs, and the available scientific evidence, which remains limited. For many people, evidence-based treatments such as psychotherapy and FDA-approved psychiatric medications continue to be the first-line approach recommended by organizations like the American Psychiatric Association.
How Low Dose Naltrexone Differs From Standard Naltrexone
The difference between standard-dose naltrexone and LDN involves more than the amount of medication taken. They are used for different clinical purposes and may produce different biological effects.
| Feature | Standard Naltrexone | Low Dose Naltrexone (LDN) |
|---|---|---|
| Typical dose | 50 mg daily (oral) | Usually 1–4.5 mg daily |
| FDA-approved uses | Alcohol use disorder and opioid use disorder | None |
| Mental health indication | Not FDA-approved | Off-label, under investigation |
| Availability | Commercially manufactured | Often prepared by a compounding pharmacy |
| Clinical evidence | Strong for approved uses | Limited and still evolving for psychiatric conditions |
Researchers are investigating whether the temporary opioid receptor blockade produced by LDN may trigger biological responses that differ from those seen with standard doses. These proposed mechanisms have led to interest in its potential role for certain psychiatric conditions, but they have not yet established LDN as a routine mental health treatment. Decisions about using LDN should be based on a careful discussion between the patient and their healthcare provider, considering both the current evidence and the availability of well-established treatment options.
How Does Low Dose Naltrexone for Mental Health Work?
Researchers believe low dose naltrexone for mental health may work by influencing several biological systems involved in mood regulation and inflammation. These proposed effects differ from those of standard-dose naltrexone, but they have not been fully confirmed in large clinical studies. As a result, scientists continue to investigate exactly how LDN may affect mental health symptoms.
One leading theory involves the body’s endorphins, which are natural chemicals that help regulate pain, stress, and emotional well-being. Because LDN temporarily blocks opioid receptors for a short period, the body may respond by increasing the production or activity of endorphins after the medication wears off. Some researchers suggest this rebound effect could support mood regulation, although the evidence remains preliminary.
Another area of interest is neuroinflammation, which refers to inflammation affecting the brain and nervous system. Researchers have found that chronic inflammation may play a role in some psychiatric conditions for certain individuals, though it is not considered the primary cause of disorders such as depression or anxiety. Laboratory and early clinical studies suggest LDN may influence immune cells in the brain, called microglia, which help regulate inflammatory responses. If these effects occur in people with mental health conditions, they could contribute to symptom improvement in some cases, but this relationship has not been firmly established.
LDN may also have immune-modulating properties, meaning it could affect how the immune system responds without broadly suppressing it. This has led researchers to study LDN in several inflammatory and autoimmune conditions alongside investigations into mental health. Even so, findings from chronic pain or autoimmune research cannot automatically be applied to psychiatric disorders because these conditions involve different biological processes.
It is important to recognize that mental health conditions rarely have a single biological cause. Genetics, brain chemistry, life experiences, physical health, sleep, stress, and social factors all interact in complex ways. Because of this, no single medication—including LDN—is expected to work for everyone.
Current clinical guidance does not recommend LDN as a first-line treatment for depression, anxiety disorders, PTSD, or bipolar disorder. Instead, if a clinician considers prescribing it, it is generally as part of a broader treatment plan that may include psychotherapy, lifestyle interventions, and medications with stronger evidence for effectiveness. Understanding these proposed mechanisms helps explain why researchers remain interested in LDN, but biological theories alone are not enough to demonstrate that a treatment is clinically effective.
What Does Research Say About Low Dose Naltrexone for Mental Health?
Current research suggests that low dose naltrexone shows promise in some areas of mental health, but the evidence is not strong enough to support routine clinical use. Most published studies are small, involve limited numbers of participants, or focus on specific patient groups. Larger, well-designed clinical trials are still needed to determine which conditions, if any, may benefit most from LDN and how it compares with established treatments.
For major depressive disorder, some early research has explored LDN as an adjunct therapy, meaning it is added to an existing treatment rather than used alone. A few small studies have reported improvements in depressive symptoms among certain participants, particularly those whose symptoms had not fully responded to standard antidepressants. However, these findings have not been consistently replicated, and there is currently insufficient evidence to recommend LDN as a standard treatment for depression.
Evidence is even more limited for anxiety disorders, post-traumatic stress disorder (PTSD), and bipolar disorder. While individual case reports and preliminary investigations have generated interest, they cannot establish whether LDN is effective or safe for these conditions. High-quality randomized controlled trials—the type of research that provides the strongest evidence for medical treatments—remain scarce.
Researchers are also studying whether people with psychiatric conditions accompanied by chronic pain or inflammatory disorders may respond differently to LDN. This is an area of active investigation, but no reliable biomarkers currently identify who is most likely to benefit. Until more evidence becomes available, clinicians must carefully weigh the uncertain benefits against known treatment options that have stronger scientific support.
Current Strength of Evidence
| Mental Health Condition | Current Evidence for LDN |
|---|---|
| Major depressive disorder | Limited; small studies suggest possible benefit as an adjunct treatment, but evidence is insufficient for routine use. |
| Treatment-resistant depression | Early research is encouraging but remains preliminary and requires larger clinical trials. |
| Anxiety disorders | Very limited evidence; no established role in standard treatment. |
| PTSD | Insufficient evidence to recommend routine use. |
| Bipolar disorder | Minimal evidence; should not replace guideline-recommended mood stabilizers or other established therapies. |
Because LDN remains an off-label treatment, healthcare professionals generally consider it only after reviewing the individual’s symptoms, medical history, current medications, and response to evidence-based therapies. It should not replace treatments with demonstrated effectiveness, such as psychotherapy or FDA-approved psychiatric medications.
If you are exploring medication options through telehealth, it can also help to understand how online prescribing services work and what their limitations are. Our guide to Nurx mental health medications explains which psychiatric medications may be available through virtual care and when an in-person evaluation may still be necessary.
The current body of research supports continued scientific investigation into LDN, but it does not yet establish the medication as a proven treatment for mental health disorders. Decisions about its use should be individualized and based on a discussion with a qualified healthcare professional who can balance the available evidence with each person’s unique clinical situation.
Potential Benefits, Risks, and Side Effects
Low dose naltrexone may offer benefits for some people, but these potential advantages should be considered alongside its limitations and the uncertainty of the current evidence. Because LDN is prescribed off-label for mental health conditions, healthcare providers typically evaluate it on a case-by-case basis rather than as a routine treatment option.
Some people who take LDN report improvements in mood, emotional well-being, or overall quality of life. Researchers are investigating whether these changes could be related to its proposed effects on endorphins or neuroinflammation, but it is not yet clear which individuals are most likely to benefit. Even when improvements occur, LDN is generally considered an adjunct to established treatments rather than a replacement for them.
Like any medication, LDN can cause side effects. Most reported side effects are mild and may lessen as the body adjusts to treatment. Commonly reported effects include:
- Vivid dreams or changes in sleep
- Difficulty falling asleep (especially when first starting treatment)
- Headache
- Nausea or stomach discomfort
- Fatigue
- Dizziness
Not everyone experiences side effects, and some people tolerate LDN well. If side effects become bothersome or persist, the prescribing clinician may recommend adjusting the dose or changing the timing of the medication.
One of the most important safety considerations is opioid use. Because naltrexone blocks opioid receptors, taking LDN while using opioid pain medications can reduce their effectiveness and may trigger withdrawal symptoms in people who are physically dependent on opioids. Patients should always inform their healthcare provider about all prescription medications, over-the-counter drugs, and supplements before starting LDN.
People with certain medical conditions may require additional evaluation before using LDN. For example, clinicians may review liver function, as naltrexone is processed by the liver. Although the lower doses used in LDN are different from standard-dose therapy, existing liver disease or other significant health conditions should still be discussed before treatment begins.
Myth vs. Fact
| Myth | Fact |
|---|---|
| “Because the dose is low, LDN has no risks.” | Even low doses can cause side effects, drug interactions, and may not be appropriate for everyone. |
| “LDN is FDA-approved for depression and anxiety.” | No. LDN is an off-label treatment for mental health conditions and has not received FDA approval for these uses. |
| “If LDN works for one person, it will work for everyone.” | Treatment responses vary widely, and current research has not identified who is most likely to benefit. |
| “LDN can replace antidepressants or therapy.” | There is not enough evidence to support replacing established mental health treatments with LDN. Any medication changes should be made only under medical supervision. |
A balanced discussion of potential benefits and risks helps people make informed decisions with their healthcare provider. Rather than focusing on isolated success stories, clinicians consider the full picture—including symptom severity, previous treatment response, medical history, and the quality of available evidence—before deciding whether LDN is an appropriate option.
Who May Be a Candidate—and Who Should Avoid It?
Low dose naltrexone is not appropriate for everyone. When clinicians consider prescribing it, they look at the person’s overall health, current medications, treatment history, and the strength of evidence for the condition being treated. Because low dose naltrexone for mental health remains an off-label option, it is generally considered only after a thoughtful discussion about potential benefits, limitations, and alternative treatments.
Some people may be candidates for LDN if they have persistent symptoms despite trying evidence-based therapies, cannot tolerate certain medications because of side effects, or have coexisting conditions that make their treatment plan more complex. In these situations, a clinician may consider LDN as an adjunct to—not a substitute for—standard psychiatric care. Any decision to prescribe it should involve shared decision-making, with clear expectations about what is known and what remains uncertain.
There are also situations in which LDN may not be appropriate. People currently taking opioid medications for pain management or opioid use disorder should not start naltrexone without medical supervision because it can block the effects of opioids and may precipitate withdrawal in physically dependent individuals. A healthcare provider will determine whether an adequate opioid-free interval is needed before treatment.
Pregnancy and breastfeeding require individualized medical advice because evidence on the safety of LDN during these periods is limited. Similarly, people with significant liver disease or a history of allergic reactions to naltrexone may require additional evaluation or an alternative treatment approach. Before prescribing LDN, clinicians typically review all medications and supplements to reduce the risk of interactions and ensure the treatment plan is appropriate.
Summary: Questions to Ask Your Clinician About LDN
- Why are you recommending LDN for my specific situation?
- What evidence supports its use for my condition?
- What benefits and side effects should I realistically expect?
- Could LDN interact with my current medications or supplements?
- How will we monitor whether the treatment is helping?
- What other evidence-based treatment options should I consider?
Choosing a medication is rarely about finding a single “best” option. Instead, it involves weighing the available evidence, personal preferences, medical history, and treatment goals. For many people, the safest and most effective plan combines medication management with psychotherapy, healthy lifestyle habits, and regular follow-up with a qualified mental health professional.
How Low Dose Naltrexone Fits Into Medication Management
Low-dose naltrexone may have a place in some individualized treatment plans, but it is not considered a first-line medication for psychiatric disorders. When clinicians prescribe it, they generally do so as part of a broader medication management strategy that includes regular follow-up, monitoring for side effects, and reassessment of treatment goals.
Medication management involves much more than writing a prescription. A mental health professional considers the person’s diagnosis, symptom severity, medical history, previous response to treatment, other health conditions, and potential drug interactions before recommending any medication. They also monitor whether symptoms improve over time and adjust the treatment plan if needed.
For many mental health conditions, evidence-based treatments such as antidepressants, mood stabilizers, and psychotherapy remain the standard of care because they have been studied in large clinical trials and are recommended in professional treatment guidelines. If LDN is added to a treatment plan, it is usually intended to complement these established approaches rather than replace them.
Some clinicians may also recommend lifestyle measures that support mental well-being, including consistent sleep, regular physical activity, balanced nutrition, stress management, and ongoing therapy. While these strategies cannot replace medical treatment when it is needed, they can contribute to overall recovery and improve quality of life alongside medication.
If you are comparing medication options, it can be helpful to understand how different psychiatric medications are used. For example, lithium has decades of evidence supporting its role in treating specific mood disorders, which differs significantly from the current evidence for LDN. Learn more in our guide to What Is Lithium Used for in Mental Health?
Key Takeaways
- LDN is an off-label treatment for mental health conditions and is not considered a standard first-line therapy.
- Decisions about prescribing LDN should be individualized and based on a careful review of the available evidence, medical history, and treatment goals.
- LDN is generally considered an adjunct to established treatments rather than a replacement for psychotherapy or FDA-approved psychiatric medications.
- Ongoing follow-up allows healthcare providers to monitor benefits, side effects, and whether adjustments to the treatment plan are needed.
When appropriate, clinicians may also refer patients to reliable educational resources from the National Institute of Mental Health (NIMH) to better understand mental health medications and treatment options.
When to Talk With a Mental Health Provider
A conversation with a mental health provider is appropriate if emotional or behavioral symptoms begin affecting your daily life, relationships, work, or school. While learning about emerging treatments like low-dose naltrexone can be helpful, deciding whether a medication is appropriate requires an individualized medical evaluation rather than self-treatment.
Consider scheduling an appointment if you experience:
- Persistent sadness, anxiety, or irritability lasting more than a few weeks
- Loss of interest in activities you previously enjoyed
- Significant changes in sleep, appetite, or energy levels
- Difficulty concentrating or completing daily responsibilities
- Symptoms that continue despite therapy or current medication
- Side effects or concerns about your existing treatment plan
- Questions about whether an off-label medication may be appropriate for your situation
During the evaluation, a healthcare professional will review your symptoms, medical history, current medications, family history, and treatment goals. They may also use standardized assessment tools, such as the Patient Health Questionnaire-9 (PHQ-9) or Generalized Anxiety Disorder-7 (GAD-7), to better understand the severity of your symptoms. This comprehensive assessment helps ensure that any treatment recommendations are based on your individual needs rather than on a single symptom or diagnosis.
If you and your clinician decide to consider LDN, they can explain what is currently known about its potential benefits and limitations, discuss possible side effects and medication interactions, and develop a plan for monitoring your progress. Regular follow-up appointments are important because they allow your treatment plan to be adjusted if your symptoms change or if the medication is not providing the expected benefit.
Some situations require immediate medical attention rather than a routine appointment. If you or someone you know is experiencing thoughts of suicide, self-harm, or harming others, call 911, go to the nearest Emergency Department, or contact the 988 Suicide & Crisis Lifeline immediately. These services provide urgent support and can connect you with trained crisis professionals.
Seeking help is a proactive step toward better mental health. Whether your provider recommends established treatments, an off-label medication such as LDN, psychotherapy, or a combination of approaches, the goal is to develop a treatment plan that is safe, evidence-based, and tailored to your individual circumstances.
Conclusion
Low-dose naltrexone (LDN) has become an area of growing interest in mental health care because of its potential effects on endorphin activity and neuroinflammation. Although early research is encouraging for some conditions, the current evidence remains limited, and LDN has not been approved by the U.S. Food and Drug Administration (FDA) for treating mental health disorders. More high-quality clinical trials are needed to better understand who may benefit, the optimal dosing, and its long-term safety.
For people considering LDN, the decision should be made with a qualified healthcare professional who can evaluate symptoms, review medical history, discuss potential benefits and risks, and recommend evidence-based treatment options. In many cases, established therapies such as psychotherapy and FDA-approved psychiatric medications continue to offer the strongest evidence for improving mental health outcomes. An individualized treatment plan, regular follow-up, and open communication with your provider remain the foundation of safe and effective medication management.
Frequently Asked Questions
1. Is low dose naltrexone approved for mental health conditions?
No. Low dose naltrexone is not approved by the FDA to treat depression, anxiety, PTSD, bipolar disorder, or other psychiatric conditions. When prescribed for mental health, it is considered an off-label medication based on a clinician’s judgment and the available evidence.
2. Can low dose naltrexone be taken with antidepressants?
In some cases, yes. LDN may be prescribed alongside certain antidepressants, but the combination should only be used under the supervision of a healthcare provider. Your clinician will review potential drug interactions, your medical history, and your treatment goals before recommending combination therapy.
3. How long does it take for low dose naltrexone to work?
There is no established timeline because LDN is still being studied for mental health conditions. Some people report noticing changes within several weeks, while others may not experience any improvement. Response varies between individuals, and treatment should be monitored by a healthcare professional.
4. What are the most common side effects of low-dose naltrexone?
Commonly reported side effects include vivid dreams, sleep changes, headache, nausea, dizziness, fatigue, and mild gastrointestinal discomfort. Many side effects are temporary, but persistent or bothersome symptoms should be discussed with your prescribing clinician.
5. Who should not take low dose naltrexone?
People currently using opioid medications or those who are physically dependent on opioids generally should not take naltrexone without medical supervision because it can trigger opioid withdrawal. Individuals with certain liver conditions or other significant medical concerns may also require additional evaluation before starting treatment.
6. Can low dose naltrexone replace therapy or standard psychiatric medications?
No. Current evidence does not support using LDN as a replacement for evidence-based treatments such as psychotherapy or FDA-approved psychiatric medications. If prescribed, it is generally considered an adjunct to a broader treatment plan.
7. Is low dose naltrexone safe for long-term use?
Long-term safety data for LDN in mental health treatment are still limited. Your healthcare provider will consider the potential benefits, risks, and ongoing monitoring needs when deciding whether continued treatment is appropriate.
Medical Review Disclosure
Medically reviewed by: Dr. Gloria Fosu, DNP, PMHNP-BC
Review Date: August 2, 2026
This article is intended for educational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Medical knowledge continues to evolve, and individual treatment decisions should always be made in consultation with a qualified healthcare professional.
CTA
Need Guidance on Mental Health Medications?
Choosing the right treatment can feel overwhelming, especially when exploring newer or off-label options like low-dose naltrexone. At Arthur Behavioral Health, our mental health professionals provide evidence-based medication management tailored to your individual needs. We can help you understand your options, answer your questions, and develop a treatment plan that aligns with current clinical guidelines and your personal health goals.
Schedule an appointment with Arthur Behavioral Health to discuss whether medication management is right for you.
References
- National Institute of Mental Health. Mental Health Medications.
- Substance Abuse and Mental Health Services Administration. TIP 63: Medications for Opioid Use Disorder.
- American Psychiatric Association. Practice Guideline for the Treatment of Patients With Major Depressive Disorder.
- National Center for Biotechnology Information. The Use of Low-Dose Naltrexone (LDN) as a Novel Anti-inflammatory Treatment for Chronic Pain.
- National Institutes of Health. Naltrexone Drug Information.
- U.S. Food and Drug Administration. Naltrexone Prescribing Information.
